Venetoclax with decitabine or azacitidine for AML

Lancet Oncol. 2018 Dec;19(12):e672. doi: 10.1016/S1470-2045(18)30824-6. Epub 2018 Nov 1.
No abstract available

Publication types

  • News

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Azacitidine / administration & dosage*
  • Azacitidine / adverse effects
  • Bridged Bicyclo Compounds, Heterocyclic / administration & dosage*
  • Bridged Bicyclo Compounds, Heterocyclic / adverse effects
  • Clinical Trials as Topic
  • Decitabine / administration & dosage*
  • Decitabine / adverse effects
  • Female
  • Humans
  • Leukemia, Myeloid, Acute / diagnosis
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / mortality
  • Male
  • Multicenter Studies as Topic
  • Sulfonamides / administration & dosage*
  • Sulfonamides / adverse effects
  • Time Factors
  • Treatment Outcome

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • Sulfonamides
  • Decitabine
  • Azacitidine
  • venetoclax